HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating for Cytokinetics (NASDAQ:CYTK) and maintained a price target of $90.
September 09, 2024 | 10:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a Buy rating for Cytokinetics, maintaining a $90 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $90 price target by a reputable analyst suggests a positive outlook for Cytokinetics, likely boosting investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100